Plasma Betatrophin Levels in Non-alcoholic Fatty Liver Disease
NCT02176811 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2014-06-27
Summary
The study searched for answers to two questions:
1-What are the plasma betatrophin levels in subjects with non-alcoholic fatty liver disease and healthy controls.
2\. Is there any relationship between plasma betatropin levels and different stage of non-alcoholic fatty liver disease 2.Is there any relationship between plasma betatropin levels and metabolic parameters in subjects with non-alcoholic fatty liver disease.
Conditions
- Non-alcoholic Fatty Liver Disease
Sponsors & Collaborators
-
Gulhane School of Medicine
lead OTHER
Eligibility
- Min Age
- 20 Years
- Max Age
- 40 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2013-06-30
- Completion
- 2014-02-28
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
A Hepatitis B With Hepatic Steatosis Study
NCT02392598 ·Status: UNKNOWN
-
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
NCT04514965 ·Status: RECRUITING
-
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
NCT06773221 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
NCT05749822 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
The Effect of Bezafibrate on Cholestatic Itch
NCT02701166 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
NCT03776175 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
NCT06078722 ·Status: UNKNOWN
-
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes
NCT06691412 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).
NCT03162419 ·Status: WITHDRAWN ·Phase: NA
-
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
NCT04454463 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
NCT04171765 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA
NCT02965911 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
NCT00375349 ·Status: WITHDRAWN ·Phase: NA
-
Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease
NCT06797011 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)
NCT05129904 ·Status: UNKNOWN
-
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
NCT06174402 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients
NCT02009592 ·Status: COMPLETED ·Phase: NA
-
Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)
NCT07104201 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
NCT02077374 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
NCT05768334 ·Status: COMPLETED ·Phase: PHASE3
-
Development of a Novel Asian Mediterranean Diet and Its Acceptability in NAFLD
NCT06321211 ·Status: COMPLETED
-
Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid
NCT02823366 ·Status: UNKNOWN ·Phase: PHASE3
-
Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis
NCT01141296 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting
NCT07021443 ·Status: COMPLETED
-
Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders
NCT02937012 ·Status: UNKNOWN ·Phase: PHASE3